HK1199881A1 - 嘧啶- -酮衍生物及其在治療、減輕或預防病毒疾病中的用途 - Google Patents

嘧啶- -酮衍生物及其在治療、減輕或預防病毒疾病中的用途

Info

Publication number
HK1199881A1
HK1199881A1 HK15100393.6A HK15100393A HK1199881A1 HK 1199881 A1 HK1199881 A1 HK 1199881A1 HK 15100393 A HK15100393 A HK 15100393A HK 1199881 A1 HK1199881 A1 HK 1199881A1
Authority
HK
Hong Kong
Prior art keywords
amelioration
pyrimidin
prevention
derivatives
treatment
Prior art date
Application number
HK15100393.6A
Other languages
English (en)
Inventor
Dirk Classen-Houben
Andrea Wolkerstorfer
Oliver Szolar
Mark Smith
Sung-Sau So
Stephen Cusack
Thierry Langer
Bruno Giethlen
Christophe Morice
Cline Michaut-Simon
Laurence Jung
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1199881A1 publication Critical patent/HK1199881A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15100393.6A 2011-10-21 2015-01-14 嘧啶- -酮衍生物及其在治療、減輕或預防病毒疾病中的用途 HK1199881A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161550057P 2011-10-21 2011-10-21
PCT/EP2012/070760 WO2013057253A1 (en) 2011-10-21 2012-10-19 Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease

Publications (1)

Publication Number Publication Date
HK1199881A1 true HK1199881A1 (zh) 2015-07-24

Family

ID=47189887

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15100393.6A HK1199881A1 (zh) 2011-10-21 2015-01-14 嘧啶- -酮衍生物及其在治療、減輕或預防病毒疾病中的用途

Country Status (12)

Country Link
US (2) US20130102601A1 (zh)
EP (1) EP2794616B1 (zh)
JP (1) JP6033873B2 (zh)
KR (1) KR20140097197A (zh)
CN (1) CN103958521B (zh)
BR (1) BR112014008412A2 (zh)
CA (1) CA2852843A1 (zh)
ES (1) ES2589459T3 (zh)
HK (1) HK1199881A1 (zh)
MX (1) MX342176B (zh)
RU (1) RU2014120477A (zh)
WO (1) WO2013057253A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016005330A1 (en) 2014-07-07 2016-01-14 F. Hoffmann-La Roche Ag Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases
AU2015306643B2 (en) * 2014-08-28 2020-05-07 X-Chem, Inc. Soluble epoxide hydrolase inhibitors and uses thereof
WO2016133888A1 (en) * 2015-02-16 2016-08-25 Biota Pharmaceuticals, Inc. Compounds for treating respiratory syncytial virus infections
LT3428170T (lt) 2015-04-28 2021-02-10 Shionogi & Co., Ltd Policiklinis piridono darinys nuo gripo ir jo provaistas
US20170081331A1 (en) 2015-09-18 2017-03-23 F. Hoffmann-La Roche Ag Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease
CA3008607A1 (en) * 2015-12-15 2017-06-22 Shionogi & Co., Ltd. A medicament for treating influenza characterized by combining a cap-dependent endonuclease inhibitor and an anti-influenza drug
EP3478671B1 (en) 2016-06-29 2020-05-13 H. Hoffnabb-La Roche Ag Pyridazinone-based broad spectrum anti-influenza inhibitors
WO2018030463A1 (ja) 2016-08-10 2018-02-15 塩野義製薬株式会社 置換された多環性ピリドン誘導体およびそのプロドラッグを含有する医薬組成物
BR112020002265A2 (pt) 2017-08-01 2020-07-28 Theravance Biopharma R&D Ip, Llc compostos pirazólicos e triazólicos bicíclicos como inibidores de jak quiinase
WO2020154350A1 (en) 2019-01-23 2020-07-30 Theravance Biopharma R&D Ip, Llc Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
US11932656B1 (en) 2023-10-06 2024-03-19 King Faisal University Thieno[2,3-d]pyrimidines as COX-2 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475109A (en) 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
ATE410429T1 (de) * 2002-03-07 2008-10-15 Hoffmann La Roche Bicyclische pyridin- und pyrimidininhibitoren von p38-kinase
EP1790638B1 (en) 2004-09-15 2013-04-03 Shionogi Co., Ltd. Carbamoylpyridone derivative having hiv integrase inhibitory activity
EP2215094B1 (en) * 2007-11-15 2016-01-27 YM BioSciences Australia Pty Ltd N-containing heterocyclic compounds
ES2543216T3 (es) 2009-03-13 2015-08-17 Katholieke Universiteit Leuven, K.U. Leuven R&D Moduladores de tiazolopirimidina como agentes inmunosupresores
JP5697163B2 (ja) 2009-03-26 2015-04-08 塩野義製薬株式会社 置換された３−ヒドロキシ−４−ピリドン誘導体
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
WO2011000566A2 (en) * 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections

Also Published As

Publication number Publication date
JP6033873B2 (ja) 2016-11-30
CN103958521A (zh) 2014-07-30
EP2794616A1 (en) 2014-10-29
CA2852843A1 (en) 2013-04-25
CN103958521B (zh) 2016-10-19
RU2014120477A (ru) 2015-11-27
MX342176B (es) 2016-09-20
MX2014003801A (es) 2015-03-11
US20160376286A1 (en) 2016-12-29
ES2589459T3 (es) 2016-11-14
BR112014008412A2 (pt) 2017-04-11
EP2794616B1 (en) 2016-06-29
KR20140097197A (ko) 2014-08-06
WO2013057253A1 (en) 2013-04-25
US20130102601A1 (en) 2013-04-25
JP2014530838A (ja) 2014-11-20

Similar Documents

Publication Publication Date Title
HK1211289A1 (zh) 二羥基嘧啶碳酸衍生物以及它們在治療、改善或預防病毒疾病中的用途
HK1212686A1 (zh) 嘧啶酮衍生物和它們用於治療、改善或預防病毒疾病的用途
HK1199881A1 (zh) 嘧啶- -酮衍生物及其在治療、減輕或預防病毒疾病中的用途
HK1205128A1 (zh) -氧代-噻唑並吡啶碳酸衍生物和它們在治療、改善或預防病毒疾病中的用途
HRP20182194T1 (hr) Onkolitički herpes simpleks virus i njegova terapeutska uporaba
IL231386A0 (en) Pyrazoloquinolinone derivatives, their preparation and medical use
HK1204987A1 (zh) 用於治療、改善或預防病毒疾病的 -氧代- -二氫-吡唑並 嘧啶衍生物
IL232256A0 (en) Purine derivatives and their use in the treatment of diseases
HK1200455A1 (zh) 可用於治療的噠嗪衍生物
HK1199640A1 (zh) 雜芳基異羥肟酸衍生物及其在治療、減輕或預防病毒疾病中的用途
HK1212688A1 (zh) 吡啶酮衍生物及其在治療、改善或預防病毒疾病中的用途
HK1211288A1 (zh) 萘啶酮衍生物及其在治療、改善或預防病毒疾病中的用途
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
EP2744786A4 (en) SUBSTITUTED 2-IMIDAZOLIDINONE AND 2-IMIDAZOLONE AND THEIR USE IN THE TREATMENT OF CANCER
LT2699545T (lt) Nauji amino-pirolino dariniai ir jų naudojimas metabolinio sindromo prevencijai ir (arba) gydymui
ZA201505093B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis
GB201102208D0 (en) Inventions and therapy
GB201102234D0 (en) Inventions and therapy
GB201102215D0 (en) Inventions and therapy
GB201102216D0 (en) Inventions and therapy
GB201102239D0 (en) Inventions and therapy
GB201102238D0 (en) Inventions and therapy
GB201102236D0 (en) Inventions and therapy
GB201102232D0 (en) Inventions and therapy
GB201102226D0 (en) Inventions and therapy

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20201021